ATRA
Price
$13.68
Change
+$0.46 (+3.48%)
Updated
Nov 21 closing price
Capitalization
98.64M
Intraday BUY SELL Signals
JAZZ
Price
$176.93
Change
+$1.19 (+0.68%)
Updated
Nov 21 closing price
Capitalization
10.75B
101 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ATRA vs JAZZ

Header iconATRA vs JAZZ Comparison
Open Charts ATRA vs JAZZBanner chart's image
Atara Biotherapeutics
Price$13.68
Change+$0.46 (+3.48%)
Volume$47.55K
Capitalization98.64M
Jazz Pharmaceuticals
Price$176.93
Change+$1.19 (+0.68%)
Volume$1.02M
Capitalization10.75B
ATRA vs JAZZ Comparison Chart in %
ATRA
Daily Signal:
Gain/Loss:
JAZZ
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATRA vs. JAZZ commentary
Nov 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATRA is a Hold and JAZZ is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 22, 2025
Stock price -- (ATRA: $13.68 vs. JAZZ: $176.93)
Brand notoriety: ATRA and JAZZ are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATRA: 77% vs. JAZZ: 101%
Market capitalization -- ATRA: $98.64M vs. JAZZ: $10.75B
ATRA [@Biotechnology] is valued at $98.64M. JAZZ’s [@Biotechnology] market capitalization is $10.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $108.28B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATRA’s FA Score shows that 0 FA rating(s) are green whileJAZZ’s FA Score has 0 green FA rating(s).

  • ATRA’s FA Score: 0 green, 5 red.
  • JAZZ’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATRA and JAZZ are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATRA’s TA Score shows that 5 TA indicator(s) are bullish while JAZZ’s TA Score has 4 bullish TA indicator(s).

  • ATRA’s TA Score: 5 bullish, 5 bearish.
  • JAZZ’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ATRA and JAZZ are a good buy in the short-term.

Price Growth

ATRA (@Biotechnology) experienced а -0.58% price change this week, while JAZZ (@Biotechnology) price change was +25.42% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.01%. For the same industry, the average monthly price growth was -3.31%, and the average quarterly price growth was +62.87%.

Reported Earning Dates

JAZZ is expected to report earnings on Mar 03, 2026.

Industries' Descriptions

@Biotechnology (-1.01% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JAZZ($10.8B) has a higher market cap than ATRA($98.6M). JAZZ has higher P/E ratio than ATRA: JAZZ (15.38) vs ATRA (4.78). JAZZ YTD gains are higher at: 43.670 vs. ATRA (2.780). JAZZ has higher annual earnings (EBITDA): 372M vs. ATRA (14.3M). JAZZ has more cash in the bank: 1.67B vs. ATRA (22.3M). ATRA has less debt than JAZZ: ATRA (17.7M) vs JAZZ (5.43B). JAZZ has higher revenues than ATRA: JAZZ (4.09B) vs ATRA (189M).
ATRAJAZZATRA / JAZZ
Capitalization98.6M10.8B1%
EBITDA14.3M372M4%
Gain YTD2.78043.6706%
P/E Ratio4.7815.3831%
Revenue189M4.09B5%
Total Cash22.3M1.67B1%
Total Debt17.7M5.43B0%
FUNDAMENTALS RATINGS
ATRA vs JAZZ: Fundamental Ratings
ATRA
JAZZ
OUTLOOK RATING
1..100
785
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
71
Overvalued
PROFIT vs RISK RATING
1..100
10076
SMR RATING
1..100
10090
PRICE GROWTH RATING
1..100
4437
P/E GROWTH RATING
1..100
9866
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATRA's Valuation (66) in the Biotechnology industry is in the same range as JAZZ (71) in the Pharmaceuticals Other industry. This means that ATRA’s stock grew similarly to JAZZ’s over the last 12 months.

JAZZ's Profit vs Risk Rating (76) in the Pharmaceuticals Other industry is in the same range as ATRA (100) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to ATRA’s over the last 12 months.

JAZZ's SMR Rating (90) in the Pharmaceuticals Other industry is in the same range as ATRA (100) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to ATRA’s over the last 12 months.

JAZZ's Price Growth Rating (37) in the Pharmaceuticals Other industry is in the same range as ATRA (44) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to ATRA’s over the last 12 months.

JAZZ's P/E Growth Rating (66) in the Pharmaceuticals Other industry is in the same range as ATRA (98) in the Biotechnology industry. This means that JAZZ’s stock grew similarly to ATRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATRAJAZZ
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
63%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
73%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
59%
MACD
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
63%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
63%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
66%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 5 days ago
60%
Declines
ODDS (%)
Bearish Trend 18 days ago
86%
Bearish Trend 3 days ago
57%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ATRA
Daily Signal:
Gain/Loss:
JAZZ
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
WBIY30.970.82
+2.72%
WBI Power Factor® High Dividend ETF
OIH281.056.64
+2.42%
VanEck Oil Services ETF
IBIL25.810.08
+0.32%
ishares Ibonds Oct 2035 Term TIPS ETF
GAPR39.300.11
+0.28%
FT Vest U.S. Eq Mod Buf ETF - Apr
ZMAY25.13N/A
N/A
Innovator Equity Dfnd Prt ETF -1 Yr May

ATRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATRA has been loosely correlated with PHAT. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ATRA jumps, then PHAT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATRA
1D Price
Change %
ATRA100%
+3.48%
PHAT - ATRA
36%
Loosely correlated
+4.42%
INVA - ATRA
33%
Poorly correlated
-0.95%
MOLN - ATRA
31%
Poorly correlated
-1.95%
ZNTL - ATRA
31%
Poorly correlated
+3.08%
JAZZ - ATRA
30%
Poorly correlated
+0.68%
More